Likes Subject
MM's holding the PPS in tight loop from retiredtech 11/30/22 2:26 PM
Market Makers are trying desperately to hold this retiredtech 11/30/22 2:12 PM
NO shares available to short which means that retiredtech 11/30/22 2:10 PM
When the price of a stock is changing,
QuantumTravesty 11/30/22 11:58 AM
Rather predictable huh? 10/30/22 Kintara Therapeutics's (NASDAQ:KTRA) short
QuantumTravesty 11/30/22 11:54 AM
Trading resumed at 9:38A. Still no answer retiredtech 11/30/22 9:39 AM
Trading Halted at 9:34A. I think buyers retiredtech 11/30/22 9:37 AM
ONLY 1.5M float. Really, really thin at retiredtech 11/29/22 1:11 PM
Yup it would not have lost 25% from QuantumTravesty 11/11/22 12:41 PM
I still say they should have let it blackcat 11/11/22 12:15 PM
Well pre-split shares have essentially met my call QuantumTravesty 11/11/22 12:04 PM
Hmmmmm INFINITI 10/19/22 11:02 AM
KTRA: Up HUGE in the 'Pre-Market' behind THAT Invest-in-America 10/19/22 9:15 AM
Premarket action on news trail being paused to kzivann 10/19/22 8:41 AM
Yes it would be the best short term QuantumTravesty 09/29/22 12:13 AM
I brought that up a couple months ago. blackcat 09/28/22 3:07 PM
Somebody on stocktwits posted this fwiw. Be interesting QuantumTravesty 09/28/22 1:21 PM
Did someone on this board say that kintara Maknmoney78 09/07/22 1:54 PM
So far no! Only lower lows. Looks like QuantumTravesty 09/06/22 3:58 PM
Are we sure this stock actually has a blackcat 09/06/22 3:20 PM
rsi 30.89 @ $0.141 is either a bounce QuantumTravesty 09/06/22 2:31 PM
Lol yes I think you’re right. QuantumTravesty 09/01/22 4:38 PM
Whoever coined the phrase "slow train wreck" surely blackcat 09/01/22 1:01 PM
Looking for a break of rsi 30 and QuantumTravesty 09/01/22 12:16 PM Maknmoney78 08/29/22 11:41 AM
Anyone else loaded up more of these .15s Maknmoney78 08/24/22 3:55 PM
My PCP thinks the CDC is looking at blackcat 08/18/22 6:17 PM
Yeah that’s a bit of what I’ve been QuantumTravesty 08/18/22 4:05 PM
We've all been planning trips "by booster shots". blackcat 08/18/22 11:17 AM
Yes on all of that! All I have QuantumTravesty 08/18/22 10:33 AM
Using a phone for trades can be hazardous! blackcat 08/18/22 9:57 AM
That’s good. That’s what I was trying to QuantumTravesty 08/18/22 9:44 AM
Haven't bought back. Just waiting................. blackcat 08/17/22 2:33 PM
Well $0.18 is the new $0.20 QuantumTravesty 08/17/22 10:58 AM
Par for their course............... blackcat 08/09/22 10:44 AM
Who’s surprised here? QuantumTravesty 08/09/22 10:20 AM
Well- I don't think it will hold- today, blackcat 08/05/22 2:34 PM
So do you think it will hold here antman 08/05/22 1:45 PM
Ugly! I knew they were bad, but didn't blackcat 08/04/22 12:55 PM
Yes and yet it could have some pumps QuantumTravesty 08/04/22 12:31 PM
We watched too many times. Toxic financing is blackcat 08/04/22 12:11 PM
Yup because they’ve now hit the bottom of QuantumTravesty 08/04/22 11:55 AM
They would be better off to just let blackcat 08/04/22 11:30 AM
I’m going to try not to rush in QuantumTravesty 08/04/22 10:28 AM
Got the 8KSpy Alert on $KTRA .....Boom........... SantaZar 08/04/22 8:39 AM
That’s a negative ghost rider the pattern is QuantumTravesty 08/03/22 2:04 PM
I have a hole in my head buying antman 08/03/22 1:38 PM
Oh yes. I'm looking for support at .20 blackcat 08/03/22 12:06 PM
Chart says they’ll try to hold support at QuantumTravesty 08/03/22 11:26 AM
Good job averaging down and going to the QuantumTravesty 08/03/22 11:23 AM
Likes Subject

11/30/22 2:26 PM
11/30/22 2:10 PM
11/30/22 11:58 AM
11/30/22 9:39 AM
11/30/22 9:37 AM
11/29/22 1:11 PM
11/11/22 12:41 PM
11/11/22 12:15 PM
11/11/22 12:04 PM
10/19/22 11:02 AM
10/19/22 9:15 AM
09/29/22 12:13 AM
09/28/22 3:07 PM
09/07/22 1:54 PM
09/06/22 3:58 PM
09/06/22 3:20 PM
09/06/22 2:31 PM
09/01/22 4:38 PM
09/01/22 12:16 PM
08/24/22 3:55 PM
08/18/22 6:17 PM
08/18/22 4:05 PM
08/18/22 10:33 AM
08/18/22 9:57 AM
08/18/22 9:44 AM
08/17/22 10:58 AM
08/09/22 10:44 AM
08/09/22 10:20 AM
08/05/22 2:34 PM
08/05/22 1:45 PM
08/04/22 12:55 PM
08/04/22 12:31 PM
08/04/22 11:55 AM
08/04/22 11:30 AM
08/04/22 10:28 AM
08/03/22 2:04 PM
08/03/22 1:38 PM
08/03/22 12:06 PM
08/03/22 11:26 AM
08/03/22 11:23 AM

Kintara Therapeutics Inc. (KTRA)

Posts (Today)
Posts (Total)
Moderators QuantumTravesty
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.

           VAL-083 Shows Potential Against Multiple Cancers 

VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.

VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.

We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.


REM-001 is a Proprietary Late Stage Photodynamic Therapy (“PDT”) Platform 

REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.

Zacks Small-Cap Research
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Valuation $5.25.   


Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.

“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
(3) VAL-083
has an established favorable safety record, both from initial trials and prior clinical use in
multiple indications.
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.

Most Liked Posts
(Last 30 Days)
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post